AstraZeneca: Pancreatic Neoplasms trials
The registry lists 19 Pancreatic Neoplasms studies with AstraZeneca as lead sponsor. 3 are open to participants now and 4 have results posted.
Phase 1 9Phase 2 8Phase 3 1No phase 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- DESTINY-PANTUMOUR04RecruitingNCT07124000
- A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering DrugsRecruitingNCT05663515
- Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid MalignanciesRecruitingNCT05417594Phase 1/2
- MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.CompletedNCT03611556Phase 1/2Results posted
- Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic CancerTerminatedNCT02570711Phase 2Results posted
- ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic CancerCompletedNCT02362048Phase 2Results posted
- Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based ChemotherapyCompletedNCT02184195Phase 3Results posted
- ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid TumorsCompletedNCT06973161
- LYNPARZA Pancreas Cancer Japan Post-Marketing Surveillance (PMS)CompletedNCT04889404
- Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid MalignanciesActive, not recruitingNCT04644068Phase 1/2
- 'OLAP' (OLAparib Regulatory Post-marketing Surveillance)CompletedNCT04553926
- A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing TumorsActive, not recruitingNCT04482309Phase 2
- Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid TumorsCompletedNCT03490669Phase 1
- AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including LymphomasCompletedNCT03205176Phase 1
- A Phase 1 Study Testing CP-675,206 In Combination With Gemcitabine In Patients With Previously Untreated, Advanced Pancreatic CancerCompletedNCT00556023Phase 1
- Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic CancerCompletedNCT00515866Phase 1
- Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid TumoursCompletedNCT00475956Phase 1
- AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine TherapyCompletedNCT00372944Phase 2
- IRESSA Combined With Radiotherapy & Gemcitabine as First-Line Treatment in Locally Advanced Pancreatic CancerCompletedNCT00234416Phase 1/2